Background. VAN remains the standard for MRSA BSI but has been associated with treatment failures and resulted in prolonged BSI durations and recurrences. In vitro studies of VAN/CFZ against MRSA demonstrated synergy and prevention of VAN resistance. However, clinical use of VAN/CFZ has not been reported. The objective of this study was to compare patient outcomes treated with VAN/CFZ vs. VAN for MRSA BSI.
Variable, n (%) VAN October 5, 2017: 12:30 PM Background. When prescribing empiric antibiotics, providers try to choose the narrowest spectrum antibiotic that will cover a patient's infection. To do this they must assess the likelihood of coverage of different regimens. We developed a model for cefazolin (or cephalexin) coverage for patients admitted to the hospital with urinary tract infections (UTI), to identify agroup of patients with a high likelihood of coverage by this first-line, narrow spectrum antibiotic. We also compared cefazolin coverage to the coverage of patients' actual empiric treatment regimens.
Methods. Patients admitted from 11/1/11 to 1/1/14 with a positive urine culture in the First 48 hours and a discharge diagnosis of UTI, were included in the dataset. Data extracted from our information warehouse included empiric antibiotic administration data, demographics, comorbidities, and past antibiotic use. Only the first eligible admission for each patient was included. A 20% random sample of patients was selected as the validation set. Logistic regression models estimated the predicted probability of cefazolin coverage.
Results. A total of 3,456 patients with an eligible UTI were included. Six hundred and Ninety-one (691) were held out for validation. Cefazolin covered 49% of the UTIs. The final model had an area under the receiver operating curve (AUC) of 69% (95% CI: 67%, 71%) in the test and 70%, (66%, 74%) in the validation set. Overall 49/65 (75%) in the highest estimated decile of cefazolin coverage had a UTI that would have been covered; only 13/66 (20%) in the lowest decile would have been covered. Of the patients in the highest decile of cefazolin coverage, 48/65 (74%) were covered by the actual empiric regimen given, however 35/65 (54%) of those regimens consisted of multiple antibiotics, and of those patients who would have been covered by cefazolin, 36/49 (73%) were empirically treated with broader spectrum antibiotics.
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Conclusion. Our findings suggest that the model can reasonably identify patients whose infections would be likely to be covered by cefazolin. Further, the majority of patients would have been covered by a narrower spectrum antibiotics than what they received.
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Disclosures. All authors: No reported disclosures. Background. Infections due to extended-spectrum β-lactamases-producing Enterobacteriaceae (ESBL-PE) pose a major public health threat due to poor outcomes and high mortality rates. Given the lack of randomized trials comparing PTZ to carbapenem in treating infections due to ESBLPE, we aimed to conduct a systematic review and meta-analysis to investigate the impact of PTZ on mortality of patients with ESBLPE bloodstream infections (BSI) compared with carbapenem.
Therapeutic efficacy of isavuconazole in experimental
Methods. MEDLINE, EMBASE, Scopus, and the Cochrane library were searched electronically for studies between 1950 and January 15, 2017 that have provided data for mortality and addressed the terms "extended spectrum β-lactamases or ESBL" and "PTZ or β-lactam/ β-lactamase inhibitor" and "carbapenem". We also searched the reference sections of included studies looking for possible missed pertinent studies. Data extraction regarding study design, characteristics of the population, intervention, comparator, and outcomes was performed.
The random-effects meta-analysis was performed with the use of StatsDirect statistical software (Version 3.0.190) .
Results. Twenty-nine cohort or case-control studies were included and analyzed; 12 evaluated definitive treatment and 17 studied empiric therapy. PTZ was associated with a non-statistically significant higher 30-day mortality than carbapenem [odds ratio (OR) 1.28, 95% CI 0.88-1.86] for ESBLPE BSI treatment (Figure) . No statistically significant differences in mortality were found between PTZ and carbapenem administered as definitive (OR 2.46, or empirical (RR 1.12, 95% CI 0.76-1.66) treatment. A subgroup analysis that included 3 studies that reported mortality based on PTZ MIC revealed that PTZ MIC >1/4 but ≤ 4/4 is associated with a non-significantly higher mortality compared with carbapenem with OR 1.33, 95% CI 0.29-6.03. All 17 patients who had a PTZ MIC≤ 0.5/4 survived after they were treated with PTZ, but the difference with carbapenem could not be estimated.
Conclusion. PTZ was not significantly associated with higher overall 30-day mortality compared with carbapenem in treating EBLPE BSI. It may be considered as alternative treatment, especially if PTZ MIC is ≤ 0.5/4. There is a need for randomized controlled trials to better guide clinical practice and limit the use of carbapenem.
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